SIFI Gains Key Approvals for AKANTIOR® in the UK
SIFI, a prominent ophthalmic company, has achieved significant milestones for its innovative treatment, AKANTIOR®. The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted Marketing Authorisation, confirming its Orphan Drug Designation, and New Active Substance status. This advancement indicates how SIFI is committed to addressing unmet medical needs regarding a rare eye condition.
Promising Innovative Medicine Designation
Just a few days prior, on May 6th, the MHRA awarded AKANTIOR® the prestigious Promising Innovative Medicine (PIM) designation. This recognition is crucial as it emphasizes AKANTIOR®’s potential to provide substantial benefits over existing treatments. The product meets important criteria: it addresses a serious and life-threatening condition, provides significant advancements over current options, and shows that benefits outweigh potential risks.
Impact on Patients with Acanthamoeba Keratitis
AKANTIOR® is recognized as the first and only approved medication specifically targeting Acanthamoeba keratitis in the UK. This eye condition, which can lead to blindness if not treated timely, predominantly affects contact lens wearers. With this new approval, patients have access to a pioneering treatment that could transform their recovery journey.
SIFI's recent authorization follows an earlier approval in the European Economic Area, widening the availability of AKANTIOR® into a key European market. This expansion into the UK means that patients who battle this extraordinary eye infection will now have a robust option in their treatment palette.
Collaboration with Healthcare Institutions
Moreover, SIFI is working closely with the National Institute for Clinical Excellence (NICE). The company anticipates submitting a comprehensive reimbursement dossier soon. This collaboration aims to secure access and coverage for AKANTIOR®, ensuring that patients truly benefit from this innovative therapy.
Manuela Marrano, Executive Director of Regulatory and Market Access at SIFI, expressed optimism about these developments. She stated, "Granting Marketing Authorization for AKANTIOR® and its recognition with the Positive PIM designation marks important progress in our mission to provide Acanthamoeba keratitis patients in the UK with access to this innovative treatment." This sentiment highlights SIFI's commitment to addressing the healthcare challenges faced by these patients.
The Science Behind AKANTIOR®
AKANTIOR® (polihexanide 0.08%) stands as a leading-edge solution specifically formulated for treating Acanthamoeba keratitis. It employs an anti-amoebic polymer, effective against both trophozoite and cyst stages of the protozoan acanthamoeba. Packaged in single-dose containers with a precise concentration of 0.08%, AKANTIOR® serves as an effective monotherapy.
Acanthamoeba keratitis presents itself as a severe corneal infection, marked by excruciating pain and intense sensitivity to light. This condition primarily impacts contact lens wearers and may require surgical interventions, including corneal transplants, if neglected. Thus, the availability of a dedicated treatment like AKANTIOR® is not only timely but necessary for enhancing patient outcomes.
SIFI's Commitment to Innovation
Founded in 1935, SIFI has established itself as an industry leader in the ophthalmic sector, spanning research, development, manufacturing, and marketing. Headquartered in Italy, the company aims to improve lives through transformative innovations in eye care. SIFI exports to over 60 countries, emphasizing its expansive reach and commitment to global health in eye care.
Frequently Asked Questions
What is AKANTIOR® used for?
AKANTIOR® is specifically developed to treat Acanthamoeba keratitis, an eye infection that can lead to serious complications.
How does AKANTIOR® work?
It employs an anti-amoebic polymer that targets both trophozoite and cyst forms of the acanthamoeba organism, providing effective treatment.
Who is eligible for AKANTIOR® treatment?
Akanthamoeba keratitis primarily affects contact lens wearers, and AKANTIOR® is suitable for adults and children aged 12 and older.
What is the significance of the PIM designation?
The Promising Innovative Medicine designation indicates that AKANTIOR® meets important criteria of addressing unmet medical needs and showing promise for significant patient benefits.
How can patients access AKANTIOR®?
SIFI is working with healthcare authorities and institutions to ensure AKANTIOR® is made widely available and accessible to those in need of treatment.
